Resveratrol-like Compounds as SIRT1 Activators.

Area of Science:

• Biochemistry
• Pharmacology
• Cell Biology

Background:

• Sirtuin 1 (SIRT1) activators like resveratrol show promise for vascular oxidative stress and endothelial dysfunction.
• Clinical application of resveratrol is hindered by poor oral bioavailability.
• Developing novel SIRT1 activators with improved pharmacokinetic properties is crucial.

Purpose of the Study:

• To identify novel resveratrol derivatives with enhanced SIRT1 activation and oral bioavailability using in silico methods.
• To evaluate the antioxidant effects of the most promising derivative, compound 3d, in human umbilical vein endothelial cells (HUVECs).

Main Methods:

• Computational screening of an in-house chemical library of resveratrol derivatives.
• In vitro evaluation of SIRT1 enzyme activation.
• Assessment of antioxidant effects of compound 3d in H2O2-treated HUVECs.
• Inhibition studies using sirtinol to confirm the role of sirtuins.

Main Results:

• Compound 3d was identified as a promising SIRT1 activator with predicted enhanced oral bioavailability.
• Compound 3d significantly preserved HUVEC viability and reduced intracellular reactive oxygen species (ROS) under oxidative stress.
• The protective effects of 3d were partially reversed by sirtinol, confirming SIRT1 involvement.
• Despite lower in vitro enzyme activation than resveratrol, 3d showed comparable cellular antioxidant effects, suggesting better cell membrane permeability.

Conclusions:

• Compound 3d represents a potential therapeutic agent for vascular oxidative stress due to its improved cellular uptake and SIRT1-mediated antioxidant activity.
• This study highlights the utility of computational approaches in designing drug candidates with improved pharmacokinetic profiles.
• Further investigation into resveratrol derivatives like 3d could lead to novel treatments for endothelial dysfunction.